These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35946480)

  • 21. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I.
    Geller DS; Rodriguez-Soriano J; Vallo Boado A; Schifter S; Bayer M; Chang SS; Lifton RP
    Nat Genet; 1998 Jul; 19(3):279-81. PubMed ID: 9662404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autosomal dominant pseudohypoaldosteronism type 1 with a novel splice site mutation in MR gene.
    Kanda K; Nozu K; Yokoyama N; Morioka I; Miwa A; Hashimura Y; Kaito H; Iijima K; Matsuo M
    BMC Nephrol; 2009 Nov; 10():37. PubMed ID: 19912655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular analysis of six Japanese patients with a renal form of pseudohypoaldosteronism type 1.
    Hatta Y; Nakamura A; Hara S; Kamijo T; Iwata J; Hamajima T; Abe M; Okada M; Ushio M; Tsuyuki K; Tajima T
    Endocr J; 2013; 60(3):299-304. PubMed ID: 23197115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural chromosome disruption of the NR3C2 gene causing pseudohypoaldosteronism type 1 presenting in infancy.
    O'Connell SM; Johnson SR; Lewis BD; Staltari L; Peverall J; Ly T; Martin AC; Jones TW; Price GJ; Murch A; Choong CS
    J Pediatr Endocrinol Metab; 2011; 24(7-8):555-9. PubMed ID: 21932599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.
    Hubert EL; Teissier R; Fernandes-Rosa FL; Fay M; Rafestin-Oblin ME; Jeunemaitre X; Metz C; Escoubet B; Zennaro MC
    J Am Soc Nephrol; 2011 Nov; 22(11):1997-2003. PubMed ID: 21903996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.
    Fernandes-Rosa FL; Hubert EL; Fagart J; Tchitchek N; Gomes D; Jouanno E; Benecke A; Rafestin-Oblin ME; Jeunemaitre X; Antonini SR; Zennaro MC
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E519-27. PubMed ID: 21159846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds.
    Viemann M; Peter M; López-Siguero JP; Simic-Schleicher G; Sippell WG
    J Clin Endocrinol Metab; 2001 May; 86(5):2056-9. PubMed ID: 11344206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1).
    Nyström AM; Bondeson ML; Skanke N; Mårtensson J; Strömberg B; Gustafsson J; Annerén G
    J Clin Endocrinol Metab; 2004 Jan; 89(1):227-31. PubMed ID: 14715854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure to thrive, hyponatremia, and hyperkalemia in a neonate.
    Sopfe J; Simmons JH
    Pediatr Ann; 2013 May; 42(5):74-9. PubMed ID: 23641881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene.
    Riepe FG; Krone N; Morlot M; Peter M; Sippell WG; Partsch CJ
    J Clin Endocrinol Metab; 2004 May; 89(5):2150-2. PubMed ID: 15126534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudohypoaldosteronisms, report on a 10-patient series.
    Belot A; Ranchin B; Fichtner C; Pujo L; Rossier BC; Liutkus A; Morlat C; Nicolino M; Zennaro MC; Cochat P
    Nephrol Dial Transplant; 2008 May; 23(5):1636-41. PubMed ID: 18424465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone resistance: structural and functional considerations and new perspectives.
    Zennaro MC; Hubert EL; Fernandes-Rosa FL
    Mol Cell Endocrinol; 2012 Mar; 350(2):206-15. PubMed ID: 21664233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Pseudohypoaldosteronism Type 1 due to 3 Novel Mutations in SCNN1Aand SCNN1BGenes.
    Cayir A; Demirelli Y; Yildiz D; Kahveci H; Yarali O; Kurnaz E; Vuralli D; Demirbilek H
    Horm Res Paediatr; 2019; 91(3):175-185. PubMed ID: 31018202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic disorders caused by gain or loss of function of the mineralocorticoid receptor].
    Arai K; Shibasaki T
    Nihon Rinsho; 2002 Feb; 60(2):361-6. PubMed ID: 11857927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular features of type 1 pseudohypoaldosteronism.
    Riepe FG
    Horm Res; 2009; 72(1):1-9. PubMed ID: 19571553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic pseudohypoaldosteronism-1 with episodic dyslipidemia in a Sudanese child.
    Abdalla A; Alhassan MA; Tawfeeg R; Sanad A; Tawamie H; Abdullah M
    Endocrinol Diabetes Metab Case Rep; 2021 Jun; 2021():. PubMed ID: 34165441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of naturally occurring NR3C2 gene mutations in Italian patients suffering from pseudohypoaldosteronism type 1.
    Balsamo A; Cicognani A; Gennari M; Sippell WG; Menabò S; Baronio F; Riepe FG
    Eur J Endocrinol; 2007 Feb; 156(2):249-56. PubMed ID: 17287415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monogenic hypertension].
    Bähr V; Oelkers W; Diederich S
    Med Klin (Munich); 2003 Apr; 98(4):208-17. PubMed ID: 12715144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudohypoaldosteronism types I and II: little more than a name in common.
    Casas-Alba D; Vila Cots J; Monfort Carretero L; Martorell Sampol L; Zennaro MC; Jeunemaitre X; Camacho Díaz JA
    J Pediatr Endocrinol Metab; 2017 May; 30(5):597-601. PubMed ID: 28593901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism.
    Sartorato P; Lapeyraque AL; Armanini D; Kuhnle U; Khaldi Y; Salomon R; Abadie V; Di Battista E; Naselli A; Racine A; Bosio M; Caprio M; Poulet-Young V; Chabrolle JP; Niaudet P; De Gennes C; Lecornec MH; Poisson E; Fusco AM; Loli P; Lombès M; Zennaro MC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2508-17. PubMed ID: 12788847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.